{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:14:16Z","timestamp":1789143256843,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T00:00:00Z","timestamp":1208217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p>\n                    <jats:bold>Objective.\u2014<\/jats:bold>\n                    To determine the efficacy of occipital nerve blocks using reconstituted botulinum toxin type\u2010A (BTX\u2010A) in providing significant and prolonged pain relief in chronic occipital neuralgia.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Background.\u2014<\/jats:bold>\n                    Occipital neuralgia is a unilateral or bilateral radiating pain with paresthesias commonly manifesting as paroxysmal episodes and involving the occipital and parietal regions. Common causes of occipital neuralgia include irritation or injury to the divisions of the occipital nerve, myofascial spasm, and focal entrapment of the occipital nerve. Treatment options include medication therapy, occipital nerve blocks, and surgical techniques. BTX\u2010A, which has shown promise in relief of other headache types, may prove a viable therapeutic option for occipital neuralgia pain.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.\u2014<\/jats:bold>\n                    Botulinum toxin type\u2010A (reconstituted in 3\u2003cc of saline) was injected into regions traversed by the greater and lesser occipital nerve in 6 subjects diagnosed with occipital neuralgia. Subjects were instructed to report their daily pain level (on a visual analog pain scale), their ability to perform daily activities (on several quality of life instruments) and their daily pain medication usage (based on a self\u2010reported log), 2\u2003weeks prior to the injection therapy and 12\u2003weeks following injection therapy. Data were analyzed for significant variation from baseline values.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    The dull\/aching and pin\/needles types of pain reported by the subjects did not show a statistically significant improvement during the trial period. The sharp\/shooting type of pain, however, showed improvement during most of the trial period except weeks 3\u20104 and 5\u20106. The quality of life measures exhibited some improvement. The headache\u2010specific quality of life measure showed significant improvement by 6\u2003weeks which continued through week 12. The general health\u2010 and depression\u2010related measures showed no statistical improvement. No significant reduction in pain medication usage was demonstrated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    Our results indicate that BTX\u2010A improved the sharp\/shooting type of pain most commonly known to be associated with occipital neuralgia. Additionally, the quality of life measures assessing burden and long\u2010term impact of the headaches, further corroborated improvement seen in daily head pain.\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2008.01089.x","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T23:31:01Z","timestamp":1208302261000},"page":"1476-1481","source":"Crossref","is-referenced-by-count":78,"title":["Botulinum Toxin Type\u2010A (BOTOX\n                    <sup>\u00ae<\/sup>\n                    ) in the Treatment of Occipital Neuralgia: A Pilot Study"],"prefix":"10.1111","volume":"48","author":[{"given":"Martin","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,19]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"158","article-title":"Occipital neuralgias: Clinical recognition of a complicated headache. A case series and literature review","volume":"11","author":"Kuhn WF","year":"1997","journal-title":"J Orofac Pain"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(05)80261-6"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00621.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1992.1201009.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00596516"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1227\/00006123-199008000-00019"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000156207.73396.8E"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01808620"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00390.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00959.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","unstructured":"KapuralL StillmanM KapuralM MekhailN.Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: A case series. American Academy of Pain Medicine 23rd Annual Meeting poster presentation 2007.","DOI":"10.1111\/j.1533-2500.2007.00150.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.2001.281.5.H2124"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00260-4"},{"key":"e_1_2_6_15_2","first-page":"310","article-title":"Status on the use of botulinum toxin for headache disorders","volume":"19","author":"Evers S.","year":"2006","journal-title":"Curr Opin Neurol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-40752"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.5.837"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1998.3804295.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(05)80261-6"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2001.218238.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2008.01089.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2008.01089.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:01:56Z","timestamp":1762074116000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2008.01089.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1526-4610.2008.01089.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01089.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}